Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.

Szer, J; Durrant, S; Schwarer, A P; Bradstock, K F; Gibson, J; Arthur, C; To, L B; Hughes, T; Raunow, H

Szer, J; Durrant, S; Schwarer, A P; Bradstock, K F; Gibson, J; Arthur, C; To, L B; Hughes, T; Raunow, H.

Affiliation

Szer J; Bone Marrow Transplant Service, The Royal Melbourne Hospital, Melbourne, Victoria, Australia. jeff.szer@mh.org.au

Intern Med J ; 34(3): 98-101, 2004 Mar.

Article in En | MEDLINE | ID: mdl-15030456

Subject(s)

Antiviral Agents/therapeutic use; Bone Marrow Transplantation; Cytomegalovirus Infections/prevention & control; Ganciclovir/administration & dosage; Postoperative Complications/prevention & control; Administration, Oral; Adolescent; Adult; Cytomegalovirus Infections/drug therapy; Humans; Infusions, Intravenous; Middle Aged; Postoperative Complications/drug therapy

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Postoperative Complications / Ganciclovir / Bone Marrow Transplantation / Cytomegalovirus Infections Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Humans / Middle aged Language: En Journal: Intern Med J Year: 2004 Document type: Article

Search on Google

XML

PubMed Links